Stoke Therapeutics, Inc. (STOK) — SEC Filings
Stoke Therapeutics, Inc. (STOK) — 39 SEC filings. Latest: ARS (Apr 22, 2026). Includes 15 8-K, 9 SC 13G/A, 6 10-Q.
View Stoke Therapeutics, Inc. on SEC EDGAR
Overview
Stoke Therapeutics, Inc. (STOK) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 5, 2025: Stoke Therapeutics, Inc. filed an 8-K on December 5, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, other events, and financial statements and exhibits. The company, incorporated in Delaware, is located at 45 Wiggins Avenue, Bedford, Massachu
Sentiment Summary
Across 39 filings, the sentiment breakdown is: 2 bearish, 36 neutral, 1 mixed. The dominant filing sentiment for Stoke Therapeutics, Inc. is neutral.
Filing Type Overview
Stoke Therapeutics, Inc. (STOK) has filed 1 ARS, 15 8-K, 6 10-Q, 1 8-K/A, 2 DEF 14A, 2 10-K, 9 SC 13G/A, 2 SC 13D/A, 1 SC 13G with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (39)
Risk Profile
Risk Assessment: Of STOK's 29 recent filings, 2 were flagged as high-risk, 10 as medium-risk, and 17 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $183.0M |
| Net Income | $51.0M |
| EPS | $0.85 |
| Debt-to-Equity | N/A |
| Cash Position | $248.3M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Patrik Blochlinger
- Dr. Barry L. Gelb
- Dr. Susan L. Robertson
- Dr. Sarah E. Michaels
- Abigail P. Johnson
Industry Context
Stoke Therapeutics operates in the highly competitive and innovative biotechnology sector, focusing on rare genetic diseases. The industry is characterized by significant R&D investment, long development cycles, and stringent regulatory hurdles. Companies like Stoke leverage advanced technologies, such as RNA-based medicines, to target unmet medical needs, often forming strategic partnerships to share costs and accelerate development.
Top Tags
8-K (4) · regulatory-filing (4) · corporate-governance (4) · filing (4) · sec-filing (4) · 10-Q (4) · pharmaceuticals (4) · financials (4) · Biotechnology (3) · amendment (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| SEC File Number | 001-38938 | Stoke Therapeutics' SEC filing identifier |
| IRS Employer Identification No. | 47-1144582 | Stoke Therapeutics' tax identification number |
| Revenue | $183.0M | for the nine months ended September 30, 2025, up from $13.9M in 2024 |
| Net Income | $51.0M | for the nine months ended September 30, 2025, compared to a $78.5M net loss in 2024 |
| Net Loss | $38.3M | for the three months ended September 30, 2025, widened from $26.4M in Q3 2024 |
| Research and Development Expenses | $96.2M | for the nine months ended September 30, 2025, up from $65.7M in 2024 |
| Cash, Cash Equivalents and Marketable Securities | $248.3M | as of September 30, 2025 |
| Q3 2025 Revenue | $10.6M | more than doubled from $4.9M in Q3 2024 |
| Shares Issued and Outstanding | 55,120,002 | as of September 30, 2025 |
| Diluted Net Income Per Share | $0.85 | for the nine months ended September 30, 2025 |
| Diluted Net Loss Per Share | ($0.65) | for the three months ended September 30, 2025 |
| Cash, Cash Equivalents, and Marketable Securities | $267.5M | as of June 30, 2025, down from $316.5M at December 31, 2024 |
| Cash Burn | $49M | for the first six months of 2025 |
| SIC Code | 2834 | Standard Industrial Classification for Pharmaceutical Preparations |
| Filing Date | 20250422 | Date the definitive proxy statement was filed. |
Forward-Looking Statements
- {"claim":"Stoke Therapeutics' stock price may experience downward pressure or increased volatility due to the significant reduction in institutional ownership by FMR LLC.","entity":"Stoke Therapeutics, Inc.","targetDate":"Within 3 months","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Stoke Therapeutics, Inc. (STOK)?
Stoke Therapeutics, Inc. has 39 recent SEC filings from Jan 2024 to Apr 2026, including 15 8-K, 9 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of STOK filings?
Across 39 filings, the sentiment breakdown is: 2 bearish, 36 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Stoke Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Stoke Therapeutics, Inc. (STOK) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Stoke Therapeutics, Inc.?
Key financial highlights from Stoke Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for STOK?
The investment thesis for STOK includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Stoke Therapeutics, Inc.?
Key executives identified across Stoke Therapeutics, Inc.'s filings include Patrik Blochlinger, Dr. Barry L. Gelb, Dr. Susan L. Robertson, Dr. Sarah E. Michaels, Abigail P. Johnson.
What are the main risk factors for Stoke Therapeutics, Inc. stock?
Of STOK's 29 assessed filings, 2 were flagged high-risk, 10 medium-risk, and 17 low-risk.
What are recent predictions and forward guidance from Stoke Therapeutics, Inc.?
Recent forward-looking statements from Stoke Therapeutics, Inc. include guidance on {"claim":"Stoke Therapeutics' stock price may experience downward pressure or increased volatility due to the significan.